Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Viewpoint
  • Published:

Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors?

Nature Clinical Practice Nephrology volume 2, pages 174–175 (2006)Cite this article

The development of selective cyclo-oxygenase 2 (COX2) inhibitors (coxibs) was intended to create a class of analgesics lacking the gastrointestinal toxicity of classical, nonselective, nonsteroidal anti-inflammatory drugs (NSAIDs). Unfortunately, since coxibs entered the market, there has been concern about the cardiovascular and renal safety of both coxibs and NSAIDs. Subsequently, an increasing number of studies have demonstrated differences in cardiovascular adverse effects among both drug classes, indicating that renal effects might also differ within each class.

Potential renal adverse effects of coxibs and nonselective NSAIDs are important in view of the association between impaired renal function, chronic kidney disease (CKD) and cardiovascular events. In addition, most cardiovascular risk factors promote CKD, and progression of CKD is associated with an increase in cardiovascular events.1

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Go AS et al. (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305

    Article  CAS  Google Scholar 

  2. Nantel F et al. (1999) Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly. FEBS Lett 457: 475–477

    Article  CAS  Google Scholar 

  3. Khan KN et al. (2001) Expression of cyclooxygenase-2 in the macula densa of human kidney in hypertension, congestive heart failure, and diabetic nephropathy. Ren Fail 23: 321–330

    Article  CAS  Google Scholar 

  4. Catella-Lawson F et al. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735–741

    CAS  PubMed  Google Scholar 

  5. Hermann M et al. (2005) Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 45: 193–197

    Article  CAS  Google Scholar 

  6. Pamuk ON and Cakir N (online 2 August 2005) The renal effects of the addition of low-dose aspirin to COX-2 selective and nonselective anti-inflammatory drugs: does aspirin cause renal dysfunction? [http://mcic3.textor.com/cgi-bin/mc/printabs.pl?APP=eular2005SCIE-abstract&TEMPLATE=&keyf=1853&showHide=show&client=] (accessed 2 August 2005)

  7. Schwartz JI et al. (2002) Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72: 50–61

    Article  CAS  Google Scholar 

  8. Whelton A et al. (2001) Cyclooxygenase-2—specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 8: 85–95

    Article  CAS  Google Scholar 

  9. Aw TJ et al. (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165: 490–496

    Article  CAS  Google Scholar 

  10. Mamdani M et al. (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363: 1751–1756

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology,

    Matthias Hermann & Thomas F Lüscher

  2. University Hospital, Zurich, Switzerland

    Matthias Hermann & Thomas F Lüscher

Authors
  1. Matthias Hermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas F Lüscher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas F Lüscher.

Ethics declarations

Competing interests

TF Lüscher received a research grant from Pfizer in 2003–2004. M Hermann has no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hermann, M., Lüscher, T. Are there differences in the renal effects of selective cyclo-oxygenase 2 inhibitors?. Nat Rev Nephrol 2, 174–175 (2006). https://doi.org/10.1038/ncpneph0131

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0131

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing